Randomised clinical trials are considered the definitive source of evidence
for guiding decisions in clinical practice. The concept of a clinical tria
l is based on sound scientific, ethical, and practical principles. The stre
ngth of evidence that an individual trial provides is assessed on the manne
r in which these principles are incorporated into the design and execution
of the trial. Since the way these principles are incorporated into a trial
is judgmental, the strength of evidence from an individual trial is a matte
r of degree. The purpose of this paper is to present some of the scientific
, ethical and practical considerations surrounding the selection of endpoin
ts and determination of sample size for trials in ovarian cancer.